Gut microbiome modulation by Weifuchun Capsules alleviates chronic atrophic gastritis: a combined microbiota and metabolomics approach

作者：Weiwei Xie, Nan Wang, Ming Wang, Qian Zhang, Wenyu Li, Huiyi Zhang, Yiran Jin, Yingfeng Du · 发表于：Frontiers in Microbiology · 年份：2025 · DOI：10.3389/fmicb.2025.1634410 · 被引用次数：4 · 研究领域：Gut microbiota and health、Traditional Chinese Medicine Studies、Helicobacter pylori-related gastroenterology studies

Background: , is widely used clinically for the management of chronic atrophic gastritis (CAG). Although previous clinical evidence has demonstrated the efficacy of WFC in alleviating symptoms and improving gastric mucosal health, the precise mechanisms, particularly those mediated by gut microbiota, remain poorly understood. Given the crucial role of intestinal microbial dysbiosis in gastrointestinal disorders, exploring the microbiota-dependent pharmacological mechanisms of WFC is essential for understanding its therapeutic benefits in CAG. Methods: We established a rat model of CAG to investigate the microbiota-associated mechanisms underlying the effects of WFC treatment. Integrated microbiome-metabolome analyses were performed, combining 16S rRNA gene sequencing for gut microbiota profiling and untargeted metabolomics to detect shifts in metabolic pathways. Network pharmacology identified bioactive compounds from 99 characterized components in WFC, with molecular docking analyses further validating these findings. Correlations between gut microbial composition and metabolic profiles were assessed using Spearman's analysis, and western blotting was employed to evaluate inflammation-associated proteins. Results: Network pharmacology screening identified 10 bioactive components from the 99 constituents present in WFC. Treatment with WFC significantly restored gut microbiota diversity and composition in CAG rats, notably enriching four bacterial families and ten genera. Meta...